Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Breast Cancer Research and Treatment
Published in: Breast Cancer Research and Treatment 3/2018

01-12-2018 | Epidemiology

Tumor grade and progesterone receptor status predict 21-gene recurrence score in early stage invasive breast carcinoma

Authors: Jing Li Huang, Scott Kizy, Schelomo Marmor, Ariella Altman, Anne Blaes, Heather Beckwith, Todd M. Tuttle, Jane Yuet Ching Hui

Published in: Breast Cancer Research and Treatment | Issue 3/2018

Login to get access

Abstract

Purpose

The 21-gene recurrence score (RS) assay is increasingly utilized to predict the risk of recurrence in early stage estrogen receptor (ER)-positive breast cancer. We hypothesize that tumor grade and progesterone receptor (PR) status predict RS categorization.

Methods

We identified women between the ages of 18 and 74 years with stage I or II, ER-positive, invasive carcinoma of the breast from the Surveillance Epidemiology End-Results database from 2010 to 2013. Multivariable logistic regression was performed to determine factors associated with high-risk RS.

Results

We identified 42,530 patients that met inclusion criteria. Multivariable logistic regression demonstrated that grade I tumors [OR (odds ratio) 0.33, 95% CI (confidence interval) 0.31–0.37] and PR positive (PR+) status (OR 0.16, 95% CI 0.15–0.17) were significantly less likely to be associated with high-risk RS. Of patients with grade I PR+ tumors, 1% was in the high-risk group by the traditional cutoffs and 4% was in the high-risk group by the TAILORx cutoffs. The percentage of patients with high-risk RS remained low for grade I PR+ tumors regardless of age, race, tumor size, and lymph node status.

Conclusions

We found that grade I PR+ tumors are associated a < 5% probability of having high-risk RS regardless of other patient demographic or pathologic factors. This suggests that the histologic factors of grade and PR status should be taken into consideration before ordering the 21-gene recurrence score assay.
Appendix
Available only for authorised users
Literature
1.
Paik S, Shak S, Tang G et al (2004) A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med 351:2817–2826CrossRef
2.
Paik S, Tang G, Shak S et al (2006) Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer. J Clin Oncol 24:3726–3734CrossRef
3.
Sparano JA, Gray RJ, Makower DF et al (2015) Prospective validation of a 21-gene expression assay in breast cancer. N Engl J Med 373:2005–2014CrossRef
4.
Albain KS, Barlow WE, Shak S et al (2010) Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with node-positive, oestrogen-receptor-positive breast cancer on chemotherapy: a retrospective analysis of a randomised trial. Lancet Oncol 11:55–65CrossRef
5.
Mamounas EP, Tang G, Fisher B, Paik S, Shak S, Constantino J, Watson D, Geyer CE, Wickerham DL, Wolmack N (2010) Association between the 21-gene recurrence score and the risk of locoreginal recurrence in node-negative, estrogen receptor-positive breast cancer: Results from NSABP B-14 and NSABP B-20. J Clin Oncol 28:1677–1683CrossRef
6.
Mamounas EP, Liu Q, Paik S, Baehner F, Tang G, Jeong JH et al (2017) 21-gene recurrence score and locoregional recurrence in node-positive/ER-positive breast cancer treated with chemo-endocrine therapy. J Natl Cancer Inst 109:1–8CrossRef
7.
Enewold L, Geiger AM, Zujewski J, Harlan LC (2015) Oncotype Dx assay and breast cancer in the United States: usage and concordance with chemotherapy. Breast Cancer Res Treat 151:149–156CrossRef
8.
Orucevic A, Heidel RE, Bell JL (2016) Utilization and impact of 21-gene recurrence score assay for breast cancer in clinical practice across the United States: lessons learned from the 2010 to 2012 National Cancer Data Base analysis. Breast Cancer Res Treat 157:427–435CrossRef
9.
Dinan MA, Mi X, Reed SD, Hirsch BR, Lyman GH, Curtis LH (2015) Initial trends in the use of the 21-gene recurrence score assay for patients with breast cancer in the medicare population, 2005–2009. JAMA Oncol 1:158–166CrossRef
10.
Gage MM, Rosman M, Mylander WC et al (2015) A validated model for identifying patients unlikely to benefit from the 21-gene recurrence score assay. Clin Breast Cancer 15:467–472CrossRef
11.
Orucevic A, Bell JL, McNabb AP, Heidel RE (2017) Oncotype DX breast cancer recurrence score can be predicted with a novel nomogram using clinicopathologic data. Breast Cancer Res Treat 163:51–61CrossRef
12.
Allison KH, Kandalaft PL, Sitlani CM, Dintzis SM, Gown AM (2012) Routine pathologic parameters can predict oncotype DX recurrence scores in subsets of ER positive patients: who does not always need testing? Breast Cancer Res Treat 131:413–424CrossRef
13.
Mattes MD, Mann JM, Ashamalla H, Tejwani A (2013) Routine histopathologic characteristics can predict oncotype DX(TM) recurrence score in subsets of breast cancer patients. Cancer Invest 31:604–606CrossRef
14.
Chaudhary LN, Jawa Z, Szabo A, Visotcky A, Chitambar CR (2016) Relevance of progesterone receptor immunohistochemical staining to Oncotype DX recurrence score. Hematol Oncol Stem Cell Ther 9:48–54CrossRef
15.
Onoda T, Yamauchi H, Yagata H et al (2015) The value of progesterone receptor expression in predicting the Recurrence Score for hormone-receptor positive invasive breast cancer patients. Breast Cancer 22:406–412CrossRef
16.
Cui X, Schiff R, Arpino G, Osborne CK, Lee AV (2005) Biology of progesterone receptor loss in breast cancer and its implications for endocrine therapy. J Clin Oncol 23:7721–7735CrossRef
17.
Viale G, Regan MM, Maiorano E, Mastropasqua MG, Dell’Orto P, Rasmussen BB et al (2007) Prognostic and predictive value of centrally reviewed expression of estrogen and progesterone receptors in a randomized trial comparing letrozole and tamoxifen adjuvant therapy for postmenopausal early breast cancer: BIG 1–98. J Clin Oncol 25:3846–3852CrossRef
18.
Kim HS, Umbricht CB, Illei PB et al (2016) Optimizing the use of gene expression profiling in early-stage breast cancer. J Clin Oncol 34:4390–4397CrossRef
19.
Partin JF, Mamounas EP (2011) Impact of the 21-gene recurrence score assay compared with standard clinicopathologic guidelines in adjuvant therapy selection for node-negative, estrogen receptor-positive breast cancer. Ann Surg Oncol 18:3399–3406CrossRef
20.
Rakha EA, El-Sayed ME, Lee AH et al (2008) Prognostic significance of Nottingham histologic grade in invasive breast carcinoma. J Clin Oncol 26:3153–3158CrossRef
21.
Sotiriou C, Wirapati P, Loi S et al (2006) Gene expression profiling in breast cancer: understanding the molecular basis of histologic grade to improve prognosis. J Natl Cancer Inst 98:262–272CrossRef
22.
Chang JM, McCullough AE, Dueck AC, Kosirek HE, Ocal IT et al (2015) Back to basics: traditional Nottingham grade mitotic counts alone are significant in predicting survival in invasive breast carcinoma. Ann Surg Oncol suppl3:S509–515CrossRef
23.
Acs G, Esposito NN, Kiluk J, Loftus L, Laronga C (2012) A mitotically active, cellular tumor stroma and/or inflammatory cells associated with tumor cells may contribute to intermediate or high Oncotype DX Recurrence Scores in low-grade invasive breast carcinomas. Mod Path 25:556–566CrossRef
24.
Arpino G, Weiss H, Lee AV et al (2005) Estrogen receptor-positive, progesterone receptor-negative breast cancer: Association with growth factor receptor expression and tamoxifen resistance. J Natl Cancer Inst 97:1254–1261CrossRef
25.
Thakkar JP, Mehta DG (2011) A review of an unfavorable subset of breast cancer: estrogen receptor positive progesterone receptor negative. Oncologist 16:276–285CrossRef
26.
Klein ME, Dabbs DJ, Shuai Y, Brufsky A, Jankowitz R, Puhalla SL, Bhargava R (2013) Prediction of the Oncotype DX recurrence score: use of pathology-generated equations derived by linear regression analysis. Mod Path 26:658–664CrossRef
27.
Smyth L, Watson G, Walsh EM et al (2015) Economic impact of 21-gene recurrence score testing on early-stage breast cancer in Ireland. Breast Cancer Res Treat 153:573–582CrossRef
28.
Lyman GH, Cosler LE, Kuderer NM, Hornberger J (2007) Impact of a 21-gene RT-PCR assay on treatment decisions in early-stage breast cancer: an economic analysis based on prognostic and predictive validation studies. Cancer 109:1011–1018CrossRef
29.
Lamond NW, Skedgel C, Rayson D, Lethbridge L, Younis T (2012) Cost-utility of the 21-gene recurrence score assay in node-negative and node-positive breast cancer. Breast Cancer Res Treat 133:1115–1123CrossRef
30.
Turner BM, Skinner KA, Tang P et al (2015) Use of modified Magee equations and histologic criteria to predict the Oncotype DX recurrence score. Mod Pathol 28:921–931CrossRef
31.
Bueno-de-Mesquita JM, Nuyten DS, Wesseling J, van Tinteren H, Linn SC, van de Vijver MJ (2010) The impact of inter-observer variation in pathological assessment of node-negative breast cancer on clinical risk assessment and patient selection for adjuvant systemic treatment. Ann Oncol 21:40–47CrossRef
32.
Robbins PPS, de Klerk N, Dawkins H, Harvey J, Sterrett G, Ellis I, Elston C (1995) Histologic grading of breast carcinomas: a study of interobserver agreement. Hum Pathol 26:873–879CrossRef
33.
Bardou VJ, Arpino G, Elledge RM et al (2003) Progesterone receptor status significantly improves outcome prediction over estrogen receptor status alone for adjuvant endocrine therapy in two large breast cancer databases. J Clin Oncol 21:1973–1979CrossRef
Metadata
Title
Tumor grade and progesterone receptor status predict 21-gene recurrence score in early stage invasive breast carcinoma
Authors
Jing Li Huang
Scott Kizy
Schelomo Marmor
Ariella Altman
Anne Blaes
Heather Beckwith
Todd M. Tuttle
Jane Yuet Ching Hui
Publication date
01-12-2018
Publisher
Springer US
Published in
Breast Cancer Research and Treatment / Issue 3/2018
Print ISSN: 0167-6806
Electronic ISSN: 1573-7217
DOI
https://doi.org/10.1007/s10549-018-4955-z

Other articles of this Issue 3/2018

Breast Cancer Research and Treatment 3/2018 Go to the issue

Preclinical study

Micro-computed tomography enables rapid surgical margin assessment during breast conserving surgery (BCS): correlation of whole BCS micro-CT readings to final histopathology

Preclinical study

A tandem duplication of BRCA1 exons 1–19 through DHX8 exon 2 in four families with hereditary breast and ovarian cancer syndrome

Brief Report

Extracellular vesicles from triple-negative breast cancer cells promote proliferation and drug resistance in non-tumorigenic breast cells

Epidemiology

Young age at diagnosis is associated with worse prognosis in the Luminal A breast cancer subtype: a retrospective institutional cohort study

Preclinical study

CCN6 regulates IGF2BP2 and HMGA2 signaling in metaplastic carcinomas of the breast

Review

Oncoplastic Breast Consortium consensus conference on nipple-sparing mastectomy
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits